# US 2006/0079456 A1 · Vasoactive intestinal polypeptide pharmaceuticals

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0079456 A1
- Document ID: US20060079456A1
- Status: Published application
- Kind: A1
- Application number: 11/245,499
- Filed: 2005-10-07
- Published: 2006-04-13
- Earliest claimed: 2004-10-08
- Assignees: Therapei Pharmaceuticals, Inc.
- Inventors: John Nestor
- Web page: https://patentgrep.com/patent/US20060079456A1

## CPC

- C07K 14/57563: {Vasoactive intestinal peptide [VIP]; Related peptides}
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Pharmaceutical compositions relating to vasoactive intestinal polypeptides and methods for the treatment of metabolic disorders, including diabetes, insulin resistance, metabolic acidosis and obesity are presented. Methods of using the vasoactive intestinal polypeptide compositions are also disclosed.

## Claims

### Claim 1

A vasoactive intestinal polypeptide selected from the group consisting of:
(a) a polypeptide corresponding to Formula (I):
FORMULA (I)
Acyl-His-Ser-Asp-aa1-aa2-Phe-Thr-aa3-aa4-Tyr-aa5-
Arg-aa6-Arg-Lys-Gln-aa7-Ala-aa8-Lys-Lys-Tyr-Leu-
aa9-aa10-aa11-aa12-aa13-aa14-aa15-aa16-Haa-(Laa-
Laa-Haa-Haa)n-Laa-
Lys(ε-long acyl)-X
wherein:
n=1-3;
Haa is a hydrophilic amino acid;
Laa is a lipophilic amino acid;
acyl is a C2-16 acyl chain;
long acyl is a C12-24 acyl chain;
X is OH or NHR1 where R1 is H or lower alkyl, haloalkyl, or PEG;
aa1 is Gly or Ala;
aa2 is Val, Ile, or Leu;
aa3 is Asp or Arg;
aa4 is Ser or Asn;
aa5 is Ser or Thr;
aa6 is Leu or Tyr;
aa7 is Met, Leu, or Val;
aa8 is Ala or Val;
aa9 is Asn, Gln, or Ala;
aa10 is Trp, Ala, or Ser;
aa11 Ile or Val;
aa12 is Leu or Lys;
aa13 is Lys, Arg, Asn, or Gly;
aa14 is Ala or Gly;
aa15 is Lys or Arg; and
aa16 is Lys or Arg;
(b) a polypeptide corresponding to Formula (II):
FORMULA (II)
Acyl-His-Ser-Asp-aa1-aa2-Phe-Thr-aa3-aa4-Tyr-aa5-
Arg-aa6-Arg-Lys-Gln-aa7-Ala-aa8-Lys-Lys-Tyr-Leu-
aa9-aa10-aa11-aa12-aa13-aa14-aa15-aa16-Haa-(Laa-
Laa-Haa-Haa)n-Laa-
aa17-Pro-Pro-Pro-Lys(ε-
long acyl)-X
wherein:
n=1-3;
Haa is a hydrophilic amino acid;
Laa is a lipophilic amino acid;
acyl is a C2-16 acyl chain;
long acyl is a C12-24 acyl chain;
X is OH or NHR1 where R1 is H or lower alkyl, haloalkyl, or PEG;
aa1 is Gly or Ala;
aa2 is Val, Ile, or Leu;
aa3 is Asp or Arg;
aa4 is Ser or Asn;
aa5 is Ser or Thr;
aa6 is Leu or Tyr;
aa7 is Met, Leu, or Val;
aa8 is Ala or Val;
aa9 is Asn, Gln, or Ala;
aa10 is Trp, Ala, or Ser;
aa11 is Ile or Val;
aa12 is Leu or Lys;
aa13 is Lys, Arg, Asn, or Gly;
aa14 is Ala or Gly;
aa15 is Lys or Arg;
aa16 is Lys or Arg; and
aa17 is absent or Gln;
(c) a polypeptide corresponding to Formula (III):
FORMULA (III)
Acyl-His-Ser-Asp-aa1-aa2-Phe-Thr-aa3-aa4-Tyr-aa5-
Arg-aa6-Arg-Lys-Gln-aa7-Ala-aa8-Lys-Lys-Tyr-Leu-
aa9-aa10-aa11-aa12-aa13-aa14-aa15-aa16-Haa-(Laa-
Laa-Haa-Haa)n-Laa-
Lys(ε-long acyl)-PEG
wherein:
n=1-3;
Haa is a hydrophilic amino acid;
Laa is a lipophilic amino acid;
acyl is a C2-16 acyl chain;
long acyl is a C12-24 acyl chain;
aa1 is Gly or Ala;
aa2 is Val, Ile, or Leu;
aa3 is Asp or Arg;
aa4 is Ser or Asn;
aa5 is Ser or Thr;
aa6 is Leu or Tyr;
aa7 is Met, Leu, or Val;
aa8 is Ala or Val;
aa9 is Asn, Gln, or Ala;
aa10 is Trp, Ala, or Ser;
aa11 is Ile or Val;
aa12 is Leu or Lys;
aa13 is Lys, Arg, Asn, or Gly;
aa14 is Ala or Gly;
aa15 is Lys or Arg; and
aa16 is Lys or Arg; and
(d) a polypeptide selected from SEQ ID NO: 1-SEQ ID NO: 38.

### Claim 2 (depends on 1)

The polypeptide of claim 1, wherein acyl is a C4-C8 acyl chain; long acyl is a C6-C14 acyl chain; and PEG is a polyethylene glycol chain of C2-C20 chain.

### Claim 3 (depends on 1)

A method for producing the polypeptide of claim 1, said method comprising synthesizing the polypeptide by the sequential addition of protected amino acids to a peptide chain, removing the protecting groups, desalting and purifying the polypeptide.

### Claim 4 (depends on 1)

A method for producing the polypeptide of claim 1, said method comprising expressing a gene encoding said polypeptide and purifying the expressed polypeptide.

### Claim 5 (depends on 1)

An expression vector encoding the polypeptide of claim 1.

### Claim 6 (depends on 5)

A host cell transformed with an expression vector of claim 5.

### Claim 7 (depends on 1)

A pharmaceutical composition comprising an effective amount of the polypeptide of claim 1, or acceptable salt thereof, and at least one pharmaceutically acceptable carrier or excipient.

### Claim 8 (depends on 7)

The pharmaceutical composition of claim 7, further comprising an effective amount of at least one compound chosen from the group consisting of insulin, insulin analogs, incretin, incretin analogs, glucagon-like peptide, glucagon-like peptide analogs, exendin, exendin analogs, sulfonylureas, biguanides, α-glucosidase inhibitors, thiazolidinediones, peroxisome proliferator activated receptor (PPAR) agonists, PPAR antagonists and PPAR partial agonists.

### Claim 9 (depends on 1)

A method of treating elevated blood glucose levels, the method comprising administering a therapeutically effective amount of the polypeptide of claim 1.

### Claim 10 (depends on 9)

The method of claim 9, further comprising administering a therapeutically effective amount of at least one compound chosen from the group consisting of insulin, insulin analogs, incretin, incretin analogs, glucagon-like peptide, glucagon-like peptide analogs, exendin, exendin analogs, sulfonylureas, biguanides, α-glucosidase inhibitors, thiazolidinediones, PPAR agonists, PPAR antagonists and PPAR partial agonists.

### Claim 11 (depends on 1)

A method of treating diabetes, the method comprising administering a therapeutically effective amount of the polypeptide of claim 1.

### Claim 12 (depends on 11)

The method of claim 11, wherein the diabetes is Type 2 diabetes mellitus.

### Claim 13 (depends on 11)

The method of claim 11, further comprising administering a therapeutically effective amount of at least one compound chosen from the group consisting of insulin, insulin analogs, incretin, incretin analogs, glucagon-like peptide, glucagon-like peptide analogs, exendin, exendin analogs, sulfonylureas, biguanides, α-glucosidase inhibitors, thiazolidinediones, PPAR agonists, PPAR antagonists and PPAR partial agonists.

### Claim 14 (depends on 1)

A method of treating insulin resistance, the method comprising administering a therapeutically effective amount of the polypeptide of claim 1.

### Claim 15 (depends on 14)

The method of claim 14, further comprising administering a therapeutically effective amount of at least one compound chosen from the group consisting of insulin, insulin analogs, incretin, incretin analogs, glucagon-like peptide, glucagon-like peptide analogs, exendin, exendin analogs, sulfonylureas, biguanides, α-glucosidase inhibitors, thiazolidinediones, PPAR agonists, PPAR antagonists and PPAR partial agonists.

### Claim 16 (depends on 1)

A method of preventing metabolic acidosis, comprising administering a therapeutically effective amount of the polypeptide of claim 1.

### Claim 17 (depends on 16)

The method of claim 16, further comprising administering a therapeutically effective amount of at least one compound chosen from the group consisting of insulin, insulin analogs, incretin, incretin analogs, glucagon-like peptide, glucagon-like peptide analogs, exendin, exendin analogs, sulfonylureas, α-glucosidase inhibitors, thiazolidinediones, PPAR agonists, PPAR antagonists and PPAR partial agonists.

### Claim 18 (depends on 1)

A method of treating obesity, comprising administering a therapeutically effective amount of the polypeptide of claim 1.

### Claim 19 (depends on 18)

The method of claim 18, further comprising administering a therapeutically effective amount of at least one compound chosen from the group consisting of insulin, insulin analogs, incretin, incretin analogs, glucagon-like peptide, glucagon-like peptide analogs, exendin, exendin analogs, sulfonylureas, biguanides, α-glucosidase inhibitors, thiazolidinediones, PPAR agonists, PPAR antagonists and PPAR partial agonists.
